Form 4: Inovio Pharmaceuticals CFO Peter Kies Trades Shares

Inovio Pharmaceuticals CFO Peter Kies reported transactions involving restricted stock units and common stock, including tax withholdings.

Summary

• Peter Kies, CFO of Inovio Pharmaceuticals, Inc., reported transactions on May 15, 2026.
• These transactions involved the vesting and settlement of restricted stock units (RSUs) and the subsequent withholding of shares for tax obligations.
• A total of 4,771 restricted stock units vested, with a contingent right to receive one share of common stock per unit.
• The vesting schedule for the RSUs was staggered: 4,771 shares vested on May 15, 2024, 4,771 on May 15, 2025, and 4,771 on May 15, 2026.
• Shares were withheld by the issuer to cover tax obligations related to the vesting and settlement of these RSUs.
• Following these transactions, Peter Kies beneficially owns 41,413 shares of common stock directly and 375 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine equity compensation vesting and tax withholding, which are standard events for company executives.

Positives

• Vesting of restricted stock units indicates continued equity compensation for the CFO.
• The CFO's beneficial ownership of 41,413 shares directly and 375 indirectly suggests a significant personal stake in the company.

Negatives

• Withholding of shares for tax purposes reduces the net number of shares received by the reporting person.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company executives and directors. This specific filing details routine equity compensation vesting and associated tax implications for the CFO of Inovio Pharmaceuticals.

Stakeholder Impact

• Shareholders gain insight into executive compensation and potential insider share movements, though this filing represents a standard vesting event.
• Employees may observe the company's continued use of equity as a compensation tool for its executives.

Key Dates

Keywords

Form 4, SEC Filing, Inovio Pharmaceuticals, INO, Peter Kies, CFO, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership, Insider Trading